694 related articles for article (PubMed ID: 25662515)
21. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
22. Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity.
Meyn MA; Wilson MB; Abdi FA; Fahey N; Schiavone AP; Wu J; Hochrein JM; Engen JR; Smithgall TE
J Biol Chem; 2006 Oct; 281(41):30907-16. PubMed ID: 16912036
[TBL] [Abstract][Full Text] [Related]
23. Allosteric networks governing regulation and catalysis of Src-family protein tyrosine kinases: implications for disease-associated kinases.
Cheng HC; Johnson TM; Mills RD; Chong YP; Chan KC; Culvenor JG
Clin Exp Pharmacol Physiol; 2010 Jan; 37(1):93-101. PubMed ID: 19566834
[TBL] [Abstract][Full Text] [Related]
24. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
Roskoski R
Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
[TBL] [Abstract][Full Text] [Related]
25. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
[TBL] [Abstract][Full Text] [Related]
26. Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement.
Moarefi I; LaFevre-Bernt M; Sicheri F; Huse M; Lee CH; Kuriyan J; Miller WT
Nature; 1997 Feb; 385(6617):650-3. PubMed ID: 9024665
[TBL] [Abstract][Full Text] [Related]
27. Domain interactions in protein tyrosine kinase Csk.
Sondhi D; Cole PA
Biochemistry; 1999 Aug; 38(34):11147-55. PubMed ID: 10460171
[TBL] [Abstract][Full Text] [Related]
28. A Discovery Strategy for Selective Inhibitors of c-Src in Complex with the Focal Adhesion Kinase SH3/SH2-binding Region.
Moroco JA; Baumgartner MP; Rust HL; Choi HG; Hur W; Gray NS; Camacho CJ; Smithgall TE
Chem Biol Drug Des; 2015 Aug; 86(2):144-55. PubMed ID: 25376742
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of TGF-β Signaling in Tumor Cells by Small Molecule Src Family Kinase Inhibitors.
Bartscht T; Rosien B; Rades D; Kaufmann R; Biersack H; Lehnerta H; Ungefroren H
Anticancer Agents Med Chem; 2017; 17(10):1351-1356. PubMed ID: 28044939
[TBL] [Abstract][Full Text] [Related]
30. C-terminal Src kinase-homologous kinase (CHK), a unique inhibitor inactivating multiple active conformations of Src family tyrosine kinases.
Chong YP; Chan AS; Chan KC; Williamson NA; Lerner EC; Smithgall TE; Bjorge JD; Fujita DJ; Purcell AW; Scholz G; Mulhern TD; Cheng HC
J Biol Chem; 2006 Nov; 281(44):32988-99. PubMed ID: 16959780
[TBL] [Abstract][Full Text] [Related]
31. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
Remsing Rix LL; Rix U; Colinge J; Hantschel O; Bennett KL; Stranzl T; Müller A; Baumgartner C; Valent P; Augustin M; Till JH; Superti-Furga G
Leukemia; 2009 Mar; 23(3):477-85. PubMed ID: 19039322
[TBL] [Abstract][Full Text] [Related]
32. Crystal structures of the Lyn protein tyrosine kinase domain in its Apo- and inhibitor-bound state.
Williams NK; Lucet IS; Klinken SP; Ingley E; Rossjohn J
J Biol Chem; 2009 Jan; 284(1):284-291. PubMed ID: 18984583
[TBL] [Abstract][Full Text] [Related]
33. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.
Shor AC; Keschman EA; Lee FY; Muro-Cacho C; Letson GD; Trent JC; Pledger WJ; Jove R
Cancer Res; 2007 Mar; 67(6):2800-8. PubMed ID: 17363602
[TBL] [Abstract][Full Text] [Related]
34. Allosteric Modulation of Src Family Kinases with ATP-Competitive Inhibitors.
Register AC; Chakraborty S; Maly DJ
Methods Mol Biol; 2017; 1636():79-89. PubMed ID: 28730474
[TBL] [Abstract][Full Text] [Related]
35. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
[TBL] [Abstract][Full Text] [Related]
36. The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders.
Roskoski R
Pharmacol Res; 2018 Jul; 133():35-52. PubMed ID: 29704617
[TBL] [Abstract][Full Text] [Related]
37. Roles of the SH2 and SH3 domains in the regulation of neuronal Src kinase functions.
Groveman BR; Xue S; Marin V; Xu J; Ali MK; Bienkiewicz EA; Yu XM
FEBS J; 2011 Feb; 278(4):643-53. PubMed ID: 21199370
[TBL] [Abstract][Full Text] [Related]
38. Dok-R mediates attenuation of epidermal growth factor-dependent mitogen-activated protein kinase and Akt activation through processive recruitment of c-Src and Csk.
Van Slyke P; Coll ML; Master Z; Kim H; Filmus J; Dumont DJ
Mol Cell Biol; 2005 May; 25(9):3831-41. PubMed ID: 15831486
[TBL] [Abstract][Full Text] [Related]
39. Spontaneous autophosphorylation of Lyn tyrosine kinase at both its activation segment and C-terminal tail confers altered substrate specificity.
Donella-Deana A; Cesaro L; Ruzzene M; Brunati AM; Marin O; Pinna LA
Biochemistry; 1998 Feb; 37(5):1438-46. PubMed ID: 9477973
[TBL] [Abstract][Full Text] [Related]
40. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation.
Cowan-Jacob SW; Fendrich G; Manley PW; Jahnke W; Fabbro D; Liebetanz J; Meyer T
Structure; 2005 Jun; 13(6):861-71. PubMed ID: 15939018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
